Biomarkers play an essential role in the management of patients with invasive breast
cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen …

Optimal treatment outcomes for breast cancer are dependent on a timely diagnosis followed
by an organized, multidisciplinary approach to care. However, in many low‐and middle …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …

Importance ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains
typically incurable with optimal treatment undefined in later lines of therapy. The chimeric …

Purpose MONARCH 2 (ClinicalTrials. gov identifier: NCT02107703) compared the efficacy
and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus …

Highlights•This ESO-ESMO ABC 5 Clinical Practice Guideline provides key
recommendations for managing advanced breast cancer patients.•It provides updates on …

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and
metastatic breast cancer (MBC)[1]. Although treatable, MBC remains virtually an incurable …

Background The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially
overcome or delay resistance to endocrine therapy in advanced breast cancer that is …

Background The antibody–drug conjugate trastuzumab emtansine is indicated for the
treatment of patients with HER2-positive metastatic breast cancer previously treated with …

Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark
of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study …